OPTiM: A randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB/C and IV melanoma. - Concepedia

Concepedia

Publication | Closed Access

OPTiM: A randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB/C and IV melanoma.

117

Citations

0

References

2013

Year

Robert Hans Ingemar Andtbacka, Frances A. Collichio, Thomas Amatruda, Neil Senzer, Jason Chesney, Keith A. Delman, Lynn E. S̄pitler, Igor Puzanov, Susan Doleman, Yining Ye,

Journal of Clinical Oncology

Cancer ManagementImmunologyPathologyDermatologyImmunotherapyOncologyClinical OncologyGranulocyte-macrophage Colony-stimulating FactorRadiation OncologyCancer ResearchFinal TextSkin CancerIv MelanomaMelanomaAsco Daily NewsCancer TreatmentMalignant DiseaseTumor MicroenvironmentTumoral PathologyImmune Checkpoint InhibitorTalimogene LaherparepvecMedicine

Abstract

LBA9008 The full, final text of this abstract will be available at abstract.asco.org at 7:30 AM (EDT) on Saturday, June, 1, 2013, and in the Annual Meeting Proceedings online supplement to the June 20, 2013, issue of Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Saturday edition of ASCO Daily News.